We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Health‐related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
- Authors
Grainger, John D.; Blanchette, Victor S.; Grotzinger, Kelly M.; Roy, Anuja; Bussel, James B.
- Abstract
Summary: The PETIT (Eltrombopag in Pediatric Patients with Thrombocytopenia from Chronic ITP) trial showed that in children aged 1–17 years with chronic or persistent immune thrombocytopenia (ITP), eltrombopag improved platelet counts, decreased clinically significant bleeding and reduced rescue medication need. We report the health‐related quality of life (HRQoL) results from the PETIT study using the Kids' ITP Tools (KIT). A limitation was that PETIT was not powered for the HRQoL analysis. Eltrombopag did not impact children's HRQoL assessed by the KIT. Although median KIT scores in children treated with eltrombopag with platelet responses were numerically higher compared with non‐responders in some age groups, the interquartile ranges overlapped.
- Subjects
IDIOPATHIC thrombocytopenic purpura; QUALITY of life; AGE factors in disease; THROMBOPOIETIN; ELTROMBOPAG
- Publication
Angewandte Chemie, 2019, Vol 131, Issue 15, p102
- ISSN
0044-8249
- Publication type
Article
- DOI
10.1111/bjh.15732